At least seven members of Congress since 2023 have bought and sold stocks of life science companies that would gain from legislation to ban several key Chinese biotech suppliers and contractors, according to financial disclosures.
As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the center of a bill targeting Chinese biotechs.
WuXi AppTec said it has “unwavering commitment” to protecting its customer’s intellectual property, in the face of allegations it passed a US client’s information to Chinese authorities.
Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences contractors, according to federal records.
WuXi AppTec is enlisting more lobbyists to represent its interests before Congress, where China hawks have pushed for limits on how the company works with US biotech and pharma companies.
More drug companies are disclosing the potential for clinical trial delays and drug shortages if the US government blacklists a family of WuXi companies used across the biopharma industry.
Rep. Mike Gallagher (R-WI), the lead sponsor of a closely watched bill that would prevent many US biopharma companies from doing business with WuXi and potentially other Chinese biopharma companies, is leaving his post next month, the congressman announced Friday.
WuXi AppTec's 2023 sales largely reliant on the US, report says
Biotech trade association to split with China`s WuXi AppTec